| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | 3 | — | 1 | — | — | 4 | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2018 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 27.00 | 29.27 | 22.98 | 16.96 |
| Receivables | 16.80 | 18.81 | 22.89 | 25.14 |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 43.80 | 48.08 | 45.86 | 42.10 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 1,409.80 | 1,370.36 | 1,410.78 | 1,413.97 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 1,409.80 | 1,370.36 | 1,410.78 | 1,413.97 |
| 10y | 5y | 3y | |
| Sales | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 59.72 | 60.41 | — | — |
—
|
| ’25 | 55.65 | 65.09 | 62.81 | 72.07 |
255.62
|
| ’24 | 57.71 | 62.08 | 61.73 | 63.47 |
245.00
|
| ’23 | 55.91 | 58.53 | 59.39 | 66.85 |
240.68
|
| ’22 | 55.36 | 53.73 | 56.18 | 67.26 |
232.52
|
| ’21 | 55.48 | 63.56 | 61.58 | 69.92 |
250.55
|
| ’20 | 55.72 | 58.34 | 59.83 | 64.97 |
238.86
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.32) | 2.05 | — | — |
—
|
| ’25 | 0.75 | 3.47 | 4.67 | 9.10 |
17.99
|
| ’24 | 6.79 | 4.59 | 9.72 | 10.83 |
31.92
|
| ’23 | 7.35 | 4.84 | 3.25 | 6.61 |
22.06
|
| ’22 | 12.14 | 10.21 | 17.42 | 17.16 |
56.92
|
| ’21 | 1.81 | 7.17 | 14.79 | 16.69 |
40.46
|
| ’20 | 14.09 | 14.46 | 5.46 | 14.82 |
48.83
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.65) | 2.01 | — | — |
—
|
| ’25 | 0.64 | 3.29 | 4.61 | 8.99 |
17.54
|
| ’24 | 6.73 | 4.46 | 9.34 | 10.72 |
31.26
|
| ’23 | 7.28 | 4.83 | 3.04 | 6.46 |
21.61
|
| ’22 | 12.11 | 10.19 | 17.39 | 17.13 |
56.82
|
| ’21 | 1.79 | 6.41 | 14.73 | 16.53 |
39.46
|
| ’20 | 14.09 | 14.43 | 5.38 | 14.73 |
48.62
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 0.04 | (0.01) | — | — |
—
|
| ’25 | (0.03) | 0.13 | 0.04 | 0.14 |
0.28
|
| ’24 | 0.09 | 0.08 | 0.05 | 0.07 |
0.29
|
| ’23 | 0.10 | 0.12 | 0.05 | 0.21 |
0.48
|
| ’22 | (0.03) | (0.07) | (0.10) | 0.07 |
(0.13)
|
| ’21 | (0.07) | 0.10 | (0.06) | 0.77 |
0.73
|
| ’20 | (0.04) | (0.02) | (0.16) | 0.03 |
(0.22)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 1.93 | 1.64 | 1.78 | 2.90 | — | — | — |
Low Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 5.49 | 4.00 | 5.95 | 6.36 | — | — | — |
High Price
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 224 | 232 | 250 | 246 | — | — | — |
Employees
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.04 | 1.04 | 0.98 | 1.04 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 232.52 | 240.68 | 245.00 | 255.62 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 26.95% | 25.37% | 17.95% | 19.58% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 27.38 | 26.17 | 14.98 | 17.47 | — | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 11.77% | 10.88% | 6.11% | 6.83% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 26.01 | 24.44 | 14.91 | 14.59 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 5.40 | 6.06 | 6.33 | 5.63 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.64 | 4.84 | 4.93 | 5.10 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | (0.13) | 0.49 | 0.30 | 0.28 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.14 | 0.44 | 0.64 | 0.36 | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.00 | (0.01) | (0.01) | (0.01) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.13 | 0.43 | 0.63 | 0.35 | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.55 | 3.46 | 4.23 | 4.69 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 50.14 | 49.70 | 49.74 | 50.15 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | 0.00 | 5.55 | 13.37 | 17.25 | ‡‡‡‡ | ‡‡‡‡ | — |
PE Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.45 | 0.56 | 0.81 | 0.95 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.82 | 0.79 | 0.95 | 1.03 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.39 | 0.49 | 0.73 | 0.89 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.59 | 5.42 | 5.73 | 13.01 | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 56.92 | 22.06 | 31.92 | 17.99 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.10) | (0.44) | (0.66) | (0.45) | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 56.82 | 21.61 | 31.26 | 17.54 | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1,334.64) | (1,366.01) | (1,322.28) | (1,364.91) | — | — | — |
Working Cap'
|
| — | — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 9.00 | — | — | — | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (13.97) | (27.00) | (29.27) | (22.98) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 127.79 | 172.13 | 210.36 | 234.99 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.51% | 1.50% | 0.89% | 0.85% | — | — | — |
ROA
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 15.03% | 11.27% | 5.17% | 5.15% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 11.60% | 16.30% | 7.80% | 6.55% | — | — | — |
ROE
|
Citizens, Inc. (CIA), a life insurer targeting underserved Latin American markets, has staged a compelling turnaround from a scandal-plagued past—marked by SEC probes, lawsuits, and a stock crash from double digits to $1.64 lows—to emerging stability under steady leadership. Shares now trade at analyst consensus targets with 0% implied upside, yet aggressive 2025 insider buying by the CEO ($660K total, stake doubled at $3.50-$3.70/share) and GC signals deep conviction amid bottoming prices and returning profitability. Revenue has held steady at $238M-$253M (0.2% 5-year CAGR), with BVPS rebounding 66% to $4.23, positive FCF ($0.63/share), and efficiency soaring (revenue/employee at $980K post-restructuring).
Valuations scream undervaluation: trailing P/E at 13x (vs. peers’ 15-20x), P/S at 0.81x, P/B at 0.95x, and EV/Sales at 0.73x, bolstered by a net cash position ($29M excess) and deleveraging. ROE at 7.8% (2021 peak: 23.4%) and ROIC rebuilding to 5.2% highlight capital efficiency in a rising-rate tailwind for insurers, despite negative working capital typical of the sector.
Analysts forecast revenue CAGR of 12% to $274M by 2027, EPS rising to $0.36 (25% net income CAGR), and BVPS surging 53% to $6.49, with FCF supporting buybacks or dividends. Risks like Latin American geopolitics and margin dips linger, but if Q1 2026 confirms revenue/employee above $1M and ROE over 10%, CIA could rerate 20-30%—echoing its 2021 surge from pariah to contender.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.